Physician profile
Deborah C Gray
NPI 1942277520
$1,543.06
in general payments reported to CMS, 2019-2025
12 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $695 · 2023: $342 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $266.50 | 2021-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.86 | 2021-2022 | |
| Lundbeck LLC | $124.99 | 2022 | |
| Kyowa Kirin, INC. | $124.94 | 2025 | |
| Corium, LLC | $124.93 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.00 | 2022 | |
| Abbvie INC. | $118.45 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $117.09 | 2023 | Rexulti |
| Sage Therapeutics, LLC | $106.50 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.64 | 2025 | |
| Spark Therapeutics, INC. | $78.90 | 2022 | |
| Chiesi USA, INC. | $17.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.